UK market access and the opportunities for pharma

The UK market access environment faces a time of change – the result of the convergence of several major drivers of reform. The COVID-19 pandemic will reinforce trends that were already taking place. The NHS in England is in the process of yet another fundamental reorganisation. Brexit has precipitated significant adjustments to the UK regulatory system. The National Institute for Health and Care Excellence (NICE) is poised to undergo an overhaul of its methods and processes.

Read the source article at Pharmafield
2021-09-02 12:03:56